SMT201500122B - Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina - Google Patents

Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina

Info

Publication number
SMT201500122B
SMT201500122B SM201500122T SM201500122T SMT201500122B SM T201500122 B SMT201500122 B SM T201500122B SM 201500122 T SM201500122 T SM 201500122T SM 201500122 T SM201500122 T SM 201500122T SM T201500122 B SMT201500122 B SM T201500122B
Authority
SM
San Marino
Prior art keywords
erythropoientine
prolylhydroxylase
inducer
inhibitor
action
Prior art date
Application number
SM201500122T
Other languages
English (en)
Italian (it)
Inventor
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masahiro Yokota
Masakazu Terashita
Dai Motoda
Kazuhito Ueyama
Hiroyuki Abe
Takahiro Hotta
Takashi Ito
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of SMT201500122B publication Critical patent/SMT201500122B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
SM201500122T 2009-07-17 2015-05-22 Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina SMT201500122B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
SMT201500122B true SMT201500122B (it) 2015-07-09

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500122T SMT201500122B (it) 2009-07-17 2015-05-22 Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina

Country Status (29)

Country Link
US (3) US8283465B2 (xx)
EP (3) EP2746282A1 (xx)
JP (8) JP5021797B2 (xx)
KR (4) KR20180042443A (xx)
CN (1) CN102471337B (xx)
AR (1) AR077417A1 (xx)
AU (1) AU2010271732B2 (xx)
BR (1) BR112012001157A2 (xx)
CA (1) CA2768505C (xx)
CO (1) CO6430426A2 (xx)
DK (1) DK2455381T5 (xx)
ES (1) ES2477968T3 (xx)
HK (1) HK1168346A1 (xx)
HR (1) HRP20140705T1 (xx)
IL (1) IL217541A (xx)
ME (1) ME01858B (xx)
MX (1) MX2012000766A (xx)
MY (1) MY160814A (xx)
NZ (1) NZ598242A (xx)
PE (1) PE20120629A1 (xx)
PL (1) PL2455381T3 (xx)
PT (1) PT2455381E (xx)
RS (1) RS53499B1 (xx)
RU (1) RU2538963C2 (xx)
SG (1) SG178049A1 (xx)
SI (1) SI2455381T1 (xx)
SM (1) SMT201500122B (xx)
TW (1) TWI485150B (xx)
WO (1) WO2011007856A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2746282A1 (en) * 2009-07-17 2014-06-25 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
US10004718B2 (en) 2012-11-26 2018-06-26 Tohoku University Erythropoietin expression promoter
JO3781B1 (ar) 2012-12-24 2021-01-31 Cadila Healthcare Ltd مشتقات الكينولون
NZ753904A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
HUE036600T2 (hu) * 2013-10-03 2018-07-30 Kura Oncology Inc ERK inhibitorok és alkalmazási eljárások
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
KR102473897B1 (ko) 2015-05-28 2022-12-06 니뽄 다바코 산교 가부시키가이샤 당뇨병성 신증을 치료 또는 예방하는 방법
CN110214139B (zh) * 2016-11-25 2022-08-23 日本烟草产业株式会社 用于生产***并吡啶化合物的方法
JP7142406B2 (ja) 2017-05-09 2022-09-27 カインド ファーマシューティカル インドリジン誘導体及びその医学的応用
CA3074989A1 (en) * 2017-10-04 2019-04-11 Japan Tobacco Inc. Nitrogen-containing heteroaryl compound and pharmaceutical use thereof
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
KR20210057014A (ko) * 2018-09-13 2021-05-20 깃세이 야쿠힌 고교 가부시키가이샤 이미다조피리디논 화합물
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-***-[1,5-a]并喹啉类化合物的制备方法
AU2021233433A1 (en) * 2020-03-11 2022-10-06 Kissei Pharmaceutical Co., Ltd. Crystal of imidazopyridinone compound or salt thereof
EP4138825A1 (en) 2020-04-20 2023-03-01 Akebia Therapeutics Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
WO2024061172A1 (zh) * 2022-09-19 2024-03-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP4101755B2 (ja) * 2001-10-08 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー ８−アミノ−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン−６−カルボン酸アミド
CA2531796A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
RU2007106180A (ru) * 2004-08-05 2008-09-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные индола, индазола или индолина
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
KR101130592B1 (ko) * 2006-06-26 2012-04-02 워너 칠콧 컴퍼니 엘엘씨 프롤릴 히드록실라제 저해제 및 사용 방법
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2172447A4 (en) 2007-07-03 2011-08-24 Astellas Pharma Inc amide
CN101983384A (zh) * 2007-11-30 2011-03-02 葛兰素史密斯克莱有限责任公司 脯氨酰羟化酶抑制剂
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US20110039895A1 (en) 2008-04-30 2011-02-17 Glaxo Smith Kline LLC., a corporation Prolyl hydroxylase inhibitors
CA2726262A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
ES2570769T3 (es) 2008-12-19 2016-05-20 Leo Pharma As Triazolopiridinas como inhibidores fosfodiesterasa para el tratamiento de enfermedades dérmicas
EP2746282A1 (en) * 2009-07-17 2014-06-25 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer

Also Published As

Publication number Publication date
JP2017214404A (ja) 2017-12-07
US8283465B2 (en) 2012-10-09
JP2022126843A (ja) 2022-08-30
TWI485150B (zh) 2015-05-21
JP2011037841A (ja) 2011-02-24
PE20120629A1 (es) 2012-05-30
HK1168346A1 (en) 2012-12-28
SI2455381T1 (sl) 2014-08-29
DK2455381T5 (en) 2015-02-09
KR20120051704A (ko) 2012-05-22
ES2477968T9 (es) 2014-11-13
WO2011007856A1 (ja) 2011-01-20
TW201105671A (en) 2011-02-16
KR20180042443A (ko) 2018-04-25
KR20170018105A (ko) 2017-02-15
HRP20140705T1 (hr) 2014-09-12
CA2768505C (en) 2018-06-12
US20110077267A1 (en) 2011-03-31
KR101706803B1 (ko) 2017-02-14
AU2010271732B2 (en) 2016-08-25
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
CN102471337B (zh) 2014-12-10
EP2455381A1 (en) 2012-05-23
RU2538963C2 (ru) 2015-01-10
EP2746282A1 (en) 2014-06-25
MX2012000766A (es) 2012-02-08
ME01858B (me) 2014-12-20
JP2020111612A (ja) 2020-07-27
DK2455381T3 (da) 2014-07-21
EP2455381B9 (en) 2014-10-22
NZ598242A (en) 2013-09-27
CO6430426A2 (es) 2012-04-30
JP2012144571A (ja) 2012-08-02
IL217541A (en) 2014-07-31
AU2010271732A1 (en) 2012-03-08
SG178049A1 (en) 2012-03-29
JP2015003933A (ja) 2015-01-08
AR077417A1 (es) 2011-08-24
PL2455381T3 (pl) 2014-10-31
RS53499B1 (en) 2015-02-27
EP2455381A4 (en) 2012-12-12
PT2455381E (pt) 2014-06-24
JP2019019144A (ja) 2019-02-07
JP2016040321A (ja) 2016-03-24
CN102471337A (zh) 2012-05-23
US20130096155A1 (en) 2013-04-18
RU2012105467A (ru) 2013-08-27
BR112012001157A2 (pt) 2016-02-23
CA2768505A1 (en) 2011-01-20
KR101850661B1 (ko) 2018-04-19
US20160145254A1 (en) 2016-05-26
EP2455381B1 (en) 2014-05-28
KR20230165366A (ko) 2023-12-05
EP3594213A1 (en) 2020-01-15
MY160814A (en) 2017-03-31
JP6434575B2 (ja) 2018-12-05
JP5021797B2 (ja) 2012-09-12

Similar Documents

Publication Publication Date Title
SMT201500122B (it) Composto di triazolopiridina e sua azione come inibitore di prolilidrossilasi e induttore della produzione di eritropoientina
SMT201600021B (it) Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201600291B (it) Inibitori di proteasi hcv
SMT201700036B (it) Composti e composizioni come inibitori di protein chinasi
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
SMT201500043B (it) Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi
SMT201500271B (it) Inibitori di neprilisina
BR112012000934A2 (pt) cassetes e métodos de utilizacao destes
DK2504332T4 (da) Amorf form og krystallinsk form af genz 112638-hemitartrat som inhibitor af glucosylceramidsyntase
SMT201400169B (it) Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie
BR112012008483A2 (pt) combunações de um inibidor de pi3k e um inibidor de mex
BRPI1010884A2 (pt) composto inibidores hdac de alcanoilamino benzamida anilina
HK1215186A1 (zh) 炎症性疾病的抑制劑
IT1398952B1 (it) Processo di preparazione della moxifloxacina e suoi sali
SMT201500156B (it) Composti di diidropirrolonaftiridinione come inibitori di jak
SMT201500071B (it) Agenti antimalarici che sono inibitori della diidro-orotato deidrogenasi
BRPI1011267A2 (pt) inibidores de protease
DK2453858T3 (da) Fremgangsmåde
SI2506840T1 (sl) Uporabe zaviralcev faktorja, ki jih inducira hiposkija
IT1400092B1 (it) Metodo di crioconservazione di polpa dentale
IT1398549B1 (it) Silil- derivati di polisaccaridi
IT1404249B1 (it) Parete di banchina e procedimento per la sua realizzazione
DK2331548T3 (da) Proteasehæmmere
SMT201300048B (it) Cocristalli di tramadol e inibitori della cox-2